Comparison between obese and non-obese nonalcoholic fatty liver disease

키워드

참고문헌 (55)

1. Wong VW, "Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-part 1 : definition, risk factors and assessment", J Gastroenterol Hepatol, 33, pp.70~85 (2018)
2. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
3. Alberti KG, "Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity", Circulation, 120, pp.1640~1645 (2009)
4. Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
5. Le MH, "2019 Global NAFLD prevalence : a systematic review and meta-analysis", Clin Gastroenterol Hepatol, 20, pp.2809~2817 (2022)
6. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
7. Das K, "Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease", Hepatology, 51, pp.1593~1602 (2010)
8. Dela Cruz AC, "Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease", Gastroenterology, 146(5 Suppl 1), pp.S909~ (2014)
9. Wei JL, "Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients : a population study using proton-magnetic resonance spectroscopy", Am J Gastroenterol, 110, pp.1306~1314 (2015)
10. Leung JC, "Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients", Hepatology, 65, pp.54~64 (2017)
11. Hagström H, "Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease : a long-term followup study", Hepatol Commun, 2, pp.48~57 (2018)
12. Chang Y, "Alcoholic and nonalcoholic fatty liver disease and liver-related mortality : a cohort study", Am J Gastroenterol, 114, pp.620~629 (2019)
13. Golabi P, "Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality", Clin Diabetes, 37, pp.65~72 (2019)
14. Zou B, "Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016", J Intern Med, 288, pp.139~151 (2020)
15. Younes R, "Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean : time for reappraisal of BMI-driven approach?", Gut, 71, pp.382~390 (2022)
16. Staufer K, "Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed nonalcoholic fatty liver disease", J Hepatol, 77, pp.918~930 (2022)
17. Tan EX, "Non-obese non-alcoholic fatty liver disease(NAFLD)in Asia : an international registry study", Metabolism, 126, pp.154911~ (2022)
18. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
19. Cusi K, "Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis : pathophysiology and clinical implications", Gastroenterology, 142, pp.711~725 (2012)
20. Sookoian S, "Systematic review with meta-analysis : risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients", Aliment Pharmacol Ther, 46, pp.85~95 (2017)
21. Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States : impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
22. Lim U, "Propensity for intra-abdominal and hepatic adiposity varies among ethnic groups", Gastroenterology, 156, pp.966~975 (2019)
23. Goh SC, "Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia", Hepatol Int, 7, pp.548~554 (2013)
24. Chan WK, "Non-alcoholic fatty liver disease in diabetics--prevalence and predictive factors in a multiracial hospital clinic population in Malaysia", J Gastroenterol Hepatol, 28, pp.1375~1383 (2013)
25. Chan WK, "Non-alcoholic fatty liver disease in a young multiracial Asian population : a worrying ethnic predilection in Malay and Indian males", Hepatol Int, 8, pp.121~127 (2014)
26. Rampal S, "Ethnic differences in the prevalence of metabolic syndrome : results from a multi-ethnic population-based survey in Malaysia", PLoS One, 7, pp.e46365~ (2012)
27. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
28. Sookoian S, "Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3gene(PNPLA3)on the susceptibility and histological severity of nonalcoholic fatty liver disease", Hepatology, 53, pp.1883~1894 (2011)
29. Trépo E, "PNPLA3 gene in liver diseases", J Hepatol, 65, pp.399~412 (2016)
30. Lin H, "Association of genetic variations with NAFLD in lean individuals", Liver Int, 42, pp.149~160 (2022)
31. Stender S, "Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci", Nat Genet, 49, pp.842~847 (2017)
32. Zain SM, "A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease", Hum Genet, 131, pp.1145~1152 (2012)
33. Yi-Wen Ting, "Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort", Clinical and Molecular Hepatology, 27(3), pp.486~498 (2021), 대한간학회[DOI]
34. Kozlitina J, "Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 46, pp.352~356 (2014)
35. Fracanzani AL, "Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity", Clin Gastroenterol Hepatol, 15, pp.1604~1611 (2017)
36. Mouzaki M, "Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia : a separate phenotype of NAFLD?", J Clin Lipidol, 13, pp.425~431 (2019)
37. Carter A, "The global prevalence and genetic spectrum of lysosomal acid lipase deficiency : a rare condition that mimics NAFLD", J Hepatol, 70, pp.142~150 (2019)
38. Erica Jennison, "The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(1), pp.22~43 (2021), 대한간학회[DOI]
39. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
40. Wong VW, "Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese : a population study using protonmagnetic resonance spectroscopy and transient elastography", Gut, 61, pp.409~415 (2012)
41. Chan WK, "Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease", J Gastroenterol Hepatol, 37, pp.795~811 (2022)
42. Chan WK, "A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis", Hepatol Int, 9, pp.594~602 (2015)
43. Chan WK, "Optimizing use of nonalcoholic fatty liver disease fibrosis score, Fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis", Clin Gastroenterol Hepatol, 17, pp.2570~2580 (2019)
44. Eslam M, "The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease", Hepatol Int, 14, pp.889~919 (2020)
45. Fu C, "Performance of simple fibrosis scores in nonobese patients with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 18, pp.2843~2845 (2020)
46. Mózes FE, "Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis", Gut, 71, pp.1006~1019 (2022)
47. Vilar-Gomez E, "Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis", Gastroenterology, 149, pp.367~378 (2015)
48. Wong VW, "Community-based lifestyle modification programme for non-alcoholic fatty liver disease : a randomized controlled trial", J Hepatol, 59, pp.536~542 (2013)
49. Wong VW, "Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease", J Hepatol, 69, pp.1349~1356 (2018)
50. Armstrong MJ, "Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis(LEAN) : a multicentre, doubleblind, randomised, placebo-controlled phase 2 study", Lancet, 387, pp.679~690 (2016)
51. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
52. Bhanji RA, "Sarcopenia in hiding : the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis", Hepatology, 66, pp.2055~2206 (2017)
53. Wilding JPH, "Impact of semaglutide on body composition in adults with overweight or obesity : exploratory analysis of the STEP 1 study", J Endocr Soc, 5(Suppl 1), pp.A16~A17 (2021)
54. Volpe S, "Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes : a 26-week prospective real-life study", Nutrients, 14, pp.2414~ (2022)
55. Dimitrios Patoulias, "Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?", Clinical and Molecular Hepatology, 26(4), pp.582~583 (2020), 대한간학회[DOI]

관련 논문AI추천